Influence of aging on the preB cell product, λ5, and its contribution to age-related bone loss

衰老对前 B 细胞产物 α5 的影响及其对与年龄相关的骨质流失的贡献

基本信息

  • 批准号:
    10589513
  • 负责人:
  • 金额:
    $ 30.44万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-07-01 至 2024-06-30
  • 项目状态:
    已结题

项目摘要

Project Summary: Aging is associated with a decrease in bone mass that coincides with decreased numbers of early B cells (proB and preB cells). PreB cells approach the endosteum where bone forming osteoblasts and bone resorbing osteoclasts reside. PreB cells express two genes, IGLL1 and VPREB, whose proteins (λ5 and VpreB) form the surrogate light chain (SLC) that binds immunoglobulin µHC to form the cell-surface expressed preB cell receptor (preBCR). In both mice and humans, early B cell numbers and their λ5-expression decrease with age. Little is known about the role of early B cells and λ5 expression in bone homeostasis and aging. This represents a significant gap in our knowledge. Previously, we observed increased bone fragility of λ5-deficient mice. Since it is recognized that both early B cell numbers and λ5 expression normally decline with age, we reasoned that λ5 might contribute to skeletal aging. Our preliminary data show that absence of λ5 disrupts acquisition of trabecular bone, decreases trabecular bone mass and accelerates bone aging. This phenotype is more prominent in female than male mice, resembling the natural history of osteoporosis in human, and importantly this process can be reversed. Irradiated λ5-/- mice reconstituted with wild type (WT) bone marrow show recovery of trabecular bone mass, whereas loss of trabecular bone mass was observed when WT mice received λ5-/- marrow. We have identified a subset of mesenchymal stromal/stem cells (MSCs) that express λ5 protein. Similar to the aging- associated decrease in early B cell numbers, the numbers of λ5-expressing MSCs decrease with age. Our preliminary studies show that disrupting λ5, or its known ligands (heparan sulfate and galectins) in bone marrow MSC cultures, diminishes osteoblast development and function. Moreover, loss of λ5 in MSCs promotes their development into adipocytes at the expanse of osteoblasts, resulting in an MSC aging phenotype which induces increased adiposity. This suggests a role for λ5 in MSC developmental fate decision. Building on our novel findings, we will test the hypothesis that aging induces changes in λ5 expression in MSCs and early B cells that impact osteoblast development and function and lead to age-associated bone loss. Our premise is that studies using λ5-deficient (λ5-/-) and B cell-depleted (JH-/-) mice will elucidate mechanisms of λ5 control of bone homeostasis and skeletal aging. In specific Aim 1, we will determine how changes in λ5 expression affect skeletal aging. In aim 2, we will identify contributions of major cellular source(s) of λ5 to bone development and aging. In aim 3, we will determine the mechanisms by which λ5 controls bone homeostasis and aging. Our experimental approach incorporates the use of primary MSCs and early B cell co-culture, Mass Spec of early B cell secreted factors affecting MSCs, and adoptive transfer and conditional deletion to dissect the in-vivo role of λ5 during aging. The significance of this project is that successful pursuit of these aims will advance the field of osteoimmunology through identifying λ5 as a new therapeutic target for prevention and/or treatment of age- associated bone loss.
项目总结:

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Mohamed Khass其他文献

Mohamed Khass的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 30.44万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 30.44万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 30.44万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 30.44万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 30.44万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 30.44万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 30.44万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 30.44万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 30.44万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 30.44万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了